<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671850</url>
  </required_header>
  <id_info>
    <org_study_id>VT-EBV-201</org_study_id>
    <nct_id>NCT03671850</nct_id>
  </id_info>
  <brief_title>VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViGenCell Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViGenCell Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the efficacy and safety of VT-EBV-N (EBV-CTL) administration in
      ENKL patients after complete remission (CR). This is to prove the effect of VT-EBV-N
      (EBV-CTL) in prevention of ENKL relapse compared to placebo, by checking the primary endpoint
      of DFS rate (disease free survival, no relapse or death after randomization) at 2 years (103
      weeks) for the last subject enrolled. 50% of the subjects will be administered VT-EBV-N
      (EBV-CTL), while the remaining subjects will be administered a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NK/T-cell lymphoma is a malignant tumor originating in NK cells and T lymphocytes. ENKL is
      associated with Epstein-Barr virus (EBV) infection and typically occurs in the nasal area,
      being termed ENKL, nasal type.EBV is a common virus in the herpes family. EBV infection in
      patients with lowered immunity such as those with Acquired Immune Deficiency Syndrome or
      those taking immunosuppressants after bone marrow transplant may induce lymphoproliferative
      diseases or cancer.

      VT-EBV-N (EBV-CTL) is a cytotoxicity T lymphocyte (CTL) targeting EBV expressed tumor cells
      indicated for ENKL. Antigen-presenting cells derived from the patient's own blood is used to
      activate T-cells in a test tube to recognize EBV, which are then expanded in vitro and
      infused into the patient's body. Targeted immunotherapy using EBV-CTL is a safe form of
      treatment that can improve long-term disease-free survival rates by boosting antitumor
      immunity without affecting other tissues apart from tumor cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">June 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No relapse or death due to any reason after randomization</measure>
    <time_frame>Randomization (8 weeks before administration) ~ 116 weeks after treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No death after randomization</measure>
    <time_frame>Randomization (8 weeks before administration) ~ 116 weeks after treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No relapse or death due to any reason after randomization</measure>
    <time_frame>Randomization (116 weeks after treatment period) ~</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>VT-EBV-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Peripheral blood mononuclear cell, PBMC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VT-EBV-N</intervention_name>
    <description>Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)</description>
    <arm_group_label>VT-EBV-N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Peripheral blood mononuclear cell, PBMC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. EBV positive extranodal NK/T cell lymphoma (ENKL) patients pathologically confirmed
             according to WHO classification at first diagnosis

          2. Patients whose complete remission (CR) has been confirmed within 6 months before
             screening and maintained, presenting high risk of relapse due to one or more of the
             following 1) Patients who are EBV detectable at initial diagnosis, with one or more of
             the following high risk factors 60 years of age or older, Ann Arbor stage II ~ IV,
             non-nasal type disease, local invasiveness (defined with T3 or T4), elevated LDH (&gt;
             upper limit of normal)) 2) Patients confirmed to have EBV DNAemia (&gt; 2000 copies/ml)
             during or after treatment 3) Patients who achieved remission from secondary or greater
             remission induction therapy after the failure of primary remission induction, or
             achieved remission after relapse

          3. 19 years and above to 75 years and below

          4. Patients with ECOG performance criteria score of 0 to 2

          5. Patients with acceptable hematopoietic function (ANC ≥ 1.5 x 109 /L, PLT ≥ 100 x 109
             /L, Hb ≥ 9 g/dL)

          6. Patients with acceptable liver function (total bilirubin &lt; 2 x upper limit of normal,
             AST/ALT &lt; 3 x upper limit of normal)

          7. Patients with renal function of eGFR &gt; 50 or better

          8. Patients with life expectancy of 6 or longer

          9. Patients who have agreed to use two different types of birth control during the study
             period (Females of childbearing age or within 2 years after menopause have to show
             negative results in urine pregnancy test) (E.g., dual contraception using oral
             contraceptives, contraceptive implant, contraceptive injection, or contraceptive patch
             combined with intrauterine device, spermicide foam or gel, contraceptive film, vaginal
             diaphragm, cervical cap, condom, etc.)

         10. Patients who have voluntarily given written consent to participate in this study

        Exclusion Criteria:

          1. Other pathological classifications of nasal cavity lymphoma than ENKL at initial
             diagnosis

          2. Patients with ENKL that has invaded the central nervous system

          3. Patients in PR, SD or PD state, not complete remission (CR)

          4. Patients who cannot generate EBV-CTL

          5. Patients who have received allogeneic stem cell transplantations

          6. Patients with severe or uncontrolled medical disorders(diabetes exceeding HbA1C9%,
             severe hypertension exceeding 180/110 mmHg, heart failure of NYHA class Ⅲ or Ⅳ,
             myocardial infarction diagnosed within 6 months prior to screening)

          7. Patients with apparent infection (HIV infection, chronic hepatitis B, chronic
             hepatitis C, active tuberculosis, etc.)

          8. Patients with malignant tumors or previous history of malignant tumors except
             completely recovered non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma

          9. Patients currently receiving treatment for ENKL such as chemotherapy, hormone therapy,
             or immunotherapy

         10. Patients with hypersensitivity to the investigational product or pretreatment
             products, including cryoprotectants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok-Goo Cho</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dae-Hee Sohn</last_name>
    <phone>82-70-4348-7527</phone>
    <email>goriest@vigencell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun-Jung Sohn</last_name>
    <phone>82-70-4348-7527</phone>
    <email>sohnhj@vigencell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-Sik Lee, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Daegu Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungRok Do, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym Univ. Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jung Kim, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deok-Hwan Yang, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inho Kim, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinseok Kim, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Yong Kim, M.D., Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary`s Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>KS013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Goo Cho, M.D., Ph.D)</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

